Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology - United Kingdom
doi 10.1002/hon.74_2629